About Emcure Pharmaceuticals Limited
Data last updated: 09 January 2026
Emcure Pharmaceuticals Limited is a public limited company based in Pune City, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 April 1981, the company has been in operation for over 45 years.
Registered with ROC Pune under CIN L24231PN1981PLC024251. Listed.
Capital: an authorised share capital of ₹250 Cr and a paid-up capital of ₹189.57 Cr. Formerly known as Emcure Pharmaceuticals Private Limited. It is led by directors including Shailesh Kripalu Ayyangar and Vijay Keshav Gokhale.
Last AGM: 28 August 2025. Financial statements filed for year ended 31 March 2025. Office: Bt Park, Pune City, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹7,963.26 Cr, a growth of 19% compared to the previous year.
The company has a workforce of approximately 6,877 employees as per the latest available data. Its group structure includes 2 subsidiaries.
The company is associated with 3 brands - Chiral Emcure, Emcure, Gennova. As per MCA filings, the company has open charges of ₹1,881.89 Cr and satisfied charges of ₹7,024.86 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website emcure.co.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressPlot No. P – 1 & P – 2 It – Bt Park, Phase – Ii M.I.D.C., Pune City, Maharashtra, India – 411057
-
IndustryPharma, Drug Formulation & Development, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24231PN1981PLC024251. The current CIN is L24231PN1981PLC024251, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231PN1981PLC024251 | Current |
| U24231PN1981PLC024251 | Previous |
Associated Brands with Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited operates multiple associated brands including Chiral Emcure, Emcure, and Gennova. These brands represent Emcure Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Research and manufacturing of pharmaceutical APIs, formulations, and biotechnology products globally. | chiralemcure.com | |
| Developer, manufacturer, and markets a broad range of pharmaceutical products | emcure.com | |
| Biotherapeutics for life-threatening diseases are developed, produced, and commercialized. | gennova.bio |
Competitors & Alternatives of Emcure Pharmaceuticals Limited
Brands and companies operating in the same space as Emcure Pharmaceuticals Limited include Senti Biosciences, Ardelyx, Concord Biotech and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Senti Biosciences
|
Cell-based therapies for cancer treatment are developed. | San Francisco, United States, United States | 2016 |
Ardelyx
|
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | Fremont, United States, United States | 2007 |
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
Tenaya Therapeutics
|
Regenerative and gene therapeutics for heart failure are developed. | San Francisco, United States, United States | 2016 |
Orca Bio
|
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | Menlo Park, United States, United States | 2016 |
Adicet Bio
|
Immune cell therapies for cancer treatment are developed. | Menlo Park, United States, United States | 2014 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Calliditas Therapeutics
|
Provider of small molecule based drug for inflammatory kidney disease | Stockholm, Sweden, Sweden | 2004 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
DermBiont
|
Microbial therapeutics for skin diseases are developed. | Melrose, United States, United States | 2015 |
Business Activity of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is audited by B S R & CO. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| B S R & CO. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is currently managed by 13 directors, with 34 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Shailesh Kripalu Ayyangar
Also directs:
Gennova Biopharmaceuticals Limited, Zuventus Healthcare Limited, Shaily Engineering Plastics Limited and 2 more
|
Director | 16 Apr 2021 | 5 Years 2 Months | Current |
|
Vijay Keshav Gokhale
Also directs:
Zuventus Healthcare Limited, Kpit Technologies Limited
|
Director | 16 Apr 2021 | 5 Years 2 Months | Current |
|
Berjis Minoo Desai
Also directs:
Berjis Desai Capital Advisor Llp, Jupiter Metaverse Llp, Berjis Desai Iconic Brands Llp and 5 more
|
Director | 03 Apr 1997 | 29 Years 3 Months | Current |
|
Satish Ramanlal Mehta
Also directs:
Emcutix Biopharmaceuticals Limited, Zuventus Healthcare Limited
|
Managing Director | 16 Apr 1981 | 45 Years 2 Months | Current |
| Samit Satish Mehta | Whole-Time Director | 28 Jul 2022 | 3 Years 11 Months | Current |
|
Sunil Rajanikant Mehta
Also directs:
Gennova Biopharmaceuticals Limited
|
Whole-Time Director | 05 Jun 2013 | 13 Years 1 Months | Current |
Financials of Emcure Pharmaceuticals Limited FY 2026 filings available
Emcure Pharmaceuticals Limited reported revenue of ₹9,203.54 Cr (up 16.56% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹9,203.54 Cr | ₹7,896 Cr |
| Other Income | ₹12.66 Cr | ₹67.26 Cr |
| Total Income | ₹9,216.2 Cr | ₹7,963.26 Cr |
| Cost of Materials Consumed | ₹1,692.77 Cr | ₹1,526.9 Cr |
| Purchases of Stock-in-Trade | ₹2,397.25 Cr | ₹1,883.24 Cr |
| Changes in Inventories | -₹432.96 Cr | -₹263.53 Cr |
| Employee Benefit Expense | ₹1,552.2 Cr | ₹1,446.29 Cr |
| Finance Costs | ₹143.67 Cr | ₹175.78 Cr |
| Depreciation & Amortisation | ₹415.05 Cr | ₹384.13 Cr |
| Other Expenses | ₹2,129.73 Cr | ₹1,828.72 Cr |
| Total Expenses | ₹7,897.71 Cr | ₹6,981.53 Cr |
| Profit Before Exceptional Items & Tax | ₹1,318.49 Cr | ₹981.73 Cr |
| Exceptional Items | -₹31.35 Cr | -₹10.38 Cr |
| Profit Before Tax | ₹1,287.14 Cr | ₹971.35 Cr |
| Total Tax Expense | ₹345.87 Cr | ₹263.88 Cr |
| Net Profit | ₹941.27 Cr | ₹707.47 Cr |
| attributable to Owners | ₹924.36 Cr | ₹681.33 Cr |
| attributable to NCI | ₹16.91 Cr | ₹26.14 Cr |
| Other Comprehensive Income | ₹166.12 Cr | ₹31.49 Cr |
| Total Comprehensive Income | ₹1,107.39 Cr | ₹738.96 Cr |
| EBITDA (computed) | ₹1,877.21 Cr | ₹1,541.64 Cr |
| Basic EPS | ₹48.77 | ₹36.43 |
| Diluted EPS | ₹48.77 | ₹36.43 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹9,612.48 Cr | ₹8,232.72 Cr |
| Non-current Assets | ₹3,903.45 Cr | ₹3,582.82 Cr |
| Current Assets | ₹5,709.03 Cr | ₹4,649.9 Cr |
| Property, Plant & Equipment | ₹1,959.93 Cr | ₹1,953.6 Cr |
| Inventories | ₹2,397.87 Cr | ₹1,931.81 Cr |
| Trade Receivables | ₹2,562.66 Cr | ₹2,002.24 Cr |
| Cash & Equivalents | ₹136.66 Cr | ₹155.54 Cr |
| Equity (Net Worth) | ₹4,976.67 Cr | ₹4,641.55 Cr |
| Equity Share Capital | ₹189.59 Cr | ₹189.48 Cr |
| Borrowings (Non-current) | ₹252.21 Cr | ₹189.94 Cr |
| Borrowings (Current) | ₹951.87 Cr | ₹541.77 Cr |
| Total Debt (computed) | ₹1,204.08 Cr | ₹731.7 Cr |
| Current Liabilities | ₹3,912.24 Cr | ₹2,668.27 Cr |
| Total Liabilities | ₹4,635.81 Cr | ₹3,591.17 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹943.55 Cr | ₹851.71 Cr |
| Investing Cash Flow | -₹1,193.06 Cr | -₹94 Cr |
| Financing Cash Flow | ₹343.43 Cr | -₹813.96 Cr |
| Capital Expenditure | ₹360.56 Cr | ₹221.77 Cr |
| Free Cash Flow (computed) | ₹582.99 Cr | ₹629.94 Cr |
| Dividends Paid | ₹56.85 Cr | ₹0 |
| Net Change in Cash | ₹112.08 Cr | -₹58.3 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,469.7 Cr | ₹2,363.48 Cr | ₹2,269.82 Cr | ₹2,100.54 Cr | ₹2,116.25 Cr | ₹1,962.63 Cr | ₹2,001.98 Cr | ₹1,815.14 Cr |
| Other Income | ₹3.99 Cr | ₹1.85 Cr | ₹3.12 Cr | ₹3.7 Cr | ₹4.45 Cr | ₹3.9 Cr | ₹35.65 Cr | ₹23.44 Cr |
| Total Income | ₹2,473.7 Cr | ₹2,365.33 Cr | ₹2,272.95 Cr | ₹2,104.23 Cr | ₹2,120.7 Cr | ₹1,966.53 Cr | ₹2,037.64 Cr | ₹1,838.58 Cr |
| Cost of Materials Consumed | ₹418.58 Cr | ₹421.23 Cr | ₹420.46 Cr | ₹432.5 Cr | ₹403.87 Cr | ₹399.83 Cr | ₹391.49 Cr | ₹331.72 Cr |
| Purchases of Stock-in-Trade | ₹661.49 Cr | ₹560.11 Cr | ₹625.17 Cr | ₹550.48 Cr | ₹571.86 Cr | ₹428.93 Cr | ₹502.3 Cr | ₹380.15 Cr |
| Changes in Inventories | -₹76.98 Cr | -₹18.91 Cr | -₹156.1 Cr | -₹180.97 Cr | -₹83.62 Cr | -₹46.03 Cr | -₹105.12 Cr | -₹28.76 Cr |
| Employee Benefit Expense | ₹386.78 Cr | ₹387.33 Cr | ₹384.62 Cr | ₹393.47 Cr | ₹373.37 Cr | ₹366.93 Cr | ₹355.59 Cr | ₹350.4 Cr |
| Finance Costs | ₹46.4 Cr | ₹37.98 Cr | ₹32.54 Cr | ₹26.76 Cr | ₹39.03 Cr | ₹31.78 Cr | ₹46.22 Cr | ₹58.76 Cr |
| Depreciation & Amortisation | ₹106.27 Cr | ₹104.68 Cr | ₹104.64 Cr | ₹99.46 Cr | ₹96.84 Cr | ₹96.81 Cr | ₹96.9 Cr | ₹93.59 Cr |
| Other Expenses | ₹600.29 Cr | ₹520.98 Cr | ₹520.19 Cr | ₹488.28 Cr | ₹448.37 Cr | ₹458.36 Cr | ₹476.85 Cr | ₹445.32 Cr |
| Total Expenses | ₹2,142.82 Cr | ₹2,013.39 Cr | ₹1,931.53 Cr | ₹1,809.98 Cr | ₹1,849.71 Cr | ₹1,736.61 Cr | ₹1,764.23 Cr | ₹1,631.17 Cr |
| Profit Before Exceptional Items & Tax | ₹330.88 Cr | ₹351.94 Cr | ₹341.42 Cr | ₹294.26 Cr | ₹270.99 Cr | ₹229.92 Cr | ₹273.41 Cr | ₹207.41 Cr |
| Exceptional Items | ₹10.3 Cr | -₹38.15 Cr | ₹0 | -₹3.5 Cr | -₹10.38 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹341.18 Cr | ₹313.79 Cr | ₹341.42 Cr | ₹290.76 Cr | ₹260.61 Cr | ₹229.92 Cr | ₹273.41 Cr | ₹207.41 Cr |
| Total Tax Expense | ₹97.44 Cr | ₹82.42 Cr | ₹90.05 Cr | ₹75.97 Cr | ₹63.38 Cr | ₹73.83 Cr | ₹71.86 Cr | ₹54.82 Cr |
| Net Profit | ₹243.74 Cr | ₹231.37 Cr | ₹251.37 Cr | ₹214.79 Cr | ₹197.24 Cr | ₹156.09 Cr | ₹201.55 Cr | ₹152.59 Cr |
| attributable to Owners | ₹243.4 Cr | ₹230.54 Cr | ₹243.46 Cr | ₹206.95 Cr | ₹188.96 Cr | ₹153.72 Cr | ₹194.57 Cr | ₹144.08 Cr |
| attributable to NCI | ₹33.3 Lakh | ₹82.9 Lakh | ₹7.91 Cr | ₹7.84 Cr | ₹8.28 Cr | ₹2.37 Cr | ₹6.98 Cr | ₹8.51 Cr |
| Other Comprehensive Income | ₹33.04 Cr | ₹25.41 Cr | ₹28.1 Cr | ₹79.57 Cr | ₹28.43 Cr | -₹58.3 Cr | ₹62.96 Cr | -₹1.6 Cr |
| Total Comprehensive Income | ₹276.77 Cr | ₹256.78 Cr | ₹279.47 Cr | ₹294.37 Cr | ₹225.66 Cr | ₹97.79 Cr | ₹264.51 Cr | ₹150.99 Cr |
| EBITDA (computed) | ₹483.54 Cr | ₹494.6 Cr | ₹478.6 Cr | ₹420.47 Cr | ₹406.85 Cr | ₹358.5 Cr | ₹416.53 Cr | ₹359.76 Cr |
| Basic EPS | ₹12.84 | ₹12.16 | ₹12.85 | ₹10.92 | ₹9.97 | ₹8.12 | ₹10.33 | ₹7.95 |
| Diluted EPS | ₹12.84 | ₹12.16 | ₹12.85 | ₹10.92 | ₹9.97 | ₹8.12 | ₹10.33 | ₹7.95 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹5,243.19 Cr | ₹4,381.92 Cr |
| Other Income | ₹209.52 Cr | ₹118.81 Cr |
| Total Income | ₹5,452.7 Cr | ₹4,500.73 Cr |
| Cost of Materials Consumed | ₹1,475.18 Cr | ₹1,307.98 Cr |
| Purchases of Stock-in-Trade | ₹894.58 Cr | ₹825.7 Cr |
| Changes in Inventories | -₹130.94 Cr | -₹126.27 Cr |
| Employee Benefit Expense | ₹821.12 Cr | ₹782.31 Cr |
| Finance Costs | ₹118.27 Cr | ₹112.96 Cr |
| Depreciation & Amortisation | ₹246.73 Cr | ₹224.97 Cr |
| Other Expenses | ₹1,058.5 Cr | ₹945.37 Cr |
| Total Expenses | ₹4,483.44 Cr | ₹4,073.02 Cr |
| Profit Before Exceptional Items & Tax | ₹969.26 Cr | ₹427.71 Cr |
| Exceptional Items | -₹25.07 Cr | ₹0 |
| Profit Before Tax | ₹944.19 Cr | ₹427.71 Cr |
| Total Tax Expense | ₹211.23 Cr | ₹110.58 Cr |
| Net Profit | ₹732.96 Cr | ₹317.13 Cr |
| Other Comprehensive Income | ₹65 Lakh | -₹1.21 Cr |
| Total Comprehensive Income | ₹733.61 Cr | ₹315.92 Cr |
| EBITDA (computed) | ₹1,334.27 Cr | ₹765.64 Cr |
| Basic EPS | ₹38.67 | ₹16.95 |
| Diluted EPS | ₹38.67 | ₹16.95 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹6,914.04 Cr | ₹5,416.11 Cr |
| Non-current Assets | ₹3,872.98 Cr | ₹2,908.86 Cr |
| Current Assets | ₹3,041.07 Cr | ₹2,507.25 Cr |
| Property, Plant & Equipment | ₹1,444.71 Cr | ₹1,459.85 Cr |
| Inventories | ₹1,206.7 Cr | ₹1,038.18 Cr |
| Trade Receivables | ₹1,534.87 Cr | ₹1,190.56 Cr |
| Cash & Equivalents | ₹11.25 Cr | ₹8.49 Cr |
| Equity (Net Worth) | ₹3,710.6 Cr | ₹3,024.36 Cr |
| Equity Share Capital | ₹189.59 Cr | ₹189.48 Cr |
| Borrowings (Non-current) | ₹664.84 Cr | ₹406.29 Cr |
| Borrowings (Current) | ₹701.43 Cr | ₹249.53 Cr |
| Total Debt (computed) | ₹1,366.27 Cr | ₹655.82 Cr |
| Current Liabilities | ₹2,267.42 Cr | ₹1,719.16 Cr |
| Total Liabilities | ₹3,203.45 Cr | ₹2,391.75 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹423.56 Cr | ₹558.29 Cr |
| Investing Cash Flow | -₹948.1 Cr | -₹435.61 Cr |
| Financing Cash Flow | ₹525.76 Cr | -₹49.25 Cr |
| Capital Expenditure | ₹235.17 Cr | ₹196.15 Cr |
| Free Cash Flow (computed) | ₹188.39 Cr | ₹362.14 Cr |
| Dividends Paid | ₹56.85 Cr | ₹0 |
| Net Change in Cash | ₹2.51 Cr | ₹71.38 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,467.7 Cr | ₹1,418.31 Cr | ₹1,260.6 Cr | ₹1,096.57 Cr | ₹1,278.19 Cr | ₹1,028.81 Cr | ₹1,104.63 Cr | ₹970.29 Cr |
| Other Income | ₹26.94 Cr | ₹138.3 Cr | ₹22.75 Cr | ₹21.52 Cr | ₹22.4 Cr | ₹19.41 Cr | ₹54.93 Cr | ₹32.51 Cr |
| Total Income | ₹1,494.64 Cr | ₹1,556.61 Cr | ₹1,283.36 Cr | ₹1,118.1 Cr | ₹1,300.58 Cr | ₹1,048.22 Cr | ₹1,159.56 Cr | ₹1,002.8 Cr |
| Cost of Materials Consumed | ₹377.85 Cr | ₹368.53 Cr | ₹374.18 Cr | ₹354.63 Cr | ₹365.01 Cr | ₹350.91 Cr | ₹325.99 Cr | ₹266.07 Cr |
| Purchases of Stock-in-Trade | ₹253.4 Cr | ₹221.14 Cr | ₹259.86 Cr | ₹160.18 Cr | ₹259.83 Cr | ₹175.31 Cr | ₹232.11 Cr | ₹158.46 Cr |
| Changes in Inventories | ₹17.42 Cr | ₹25.71 Cr | -₹67.46 Cr | -₹106.62 Cr | -₹16.86 Cr | -₹47.69 Cr | -₹53.3 Cr | -₹8.42 Cr |
| Employee Benefit Expense | ₹202.37 Cr | ₹205.65 Cr | ₹202.68 Cr | ₹210.42 Cr | ₹198.16 Cr | ₹196.01 Cr | ₹191.12 Cr | ₹195.09 Cr |
| Finance Costs | ₹36.87 Cr | ₹33.15 Cr | ₹27.71 Cr | ₹20.54 Cr | ₹24.07 Cr | ₹19.93 Cr | ₹31.4 Cr | ₹37.57 Cr |
| Depreciation & Amortisation | ₹63.04 Cr | ₹62.14 Cr | ₹61.74 Cr | ₹59.82 Cr | ₹56.91 Cr | ₹56.65 Cr | ₹56.34 Cr | ₹55.08 Cr |
| Other Expenses | ₹245 Cr | ₹296.77 Cr | ₹266.76 Cr | ₹249.97 Cr | ₹227.41 Cr | ₹229.86 Cr | ₹256.56 Cr | ₹243.91 Cr |
| Total Expenses | ₹1,195.96 Cr | ₹1,213.09 Cr | ₹1,125.47 Cr | ₹948.93 Cr | ₹1,114.53 Cr | ₹980.97 Cr | ₹1,040.21 Cr | ₹947.75 Cr |
| Profit Before Exceptional Items & Tax | ₹298.69 Cr | ₹343.52 Cr | ₹157.89 Cr | ₹169.17 Cr | ₹186.05 Cr | ₹67.25 Cr | ₹119.36 Cr | ₹55.05 Cr |
| Exceptional Items | ₹7.58 Cr | -₹29.15 Cr | ₹0 | -₹3.5 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹306.27 Cr | ₹314.37 Cr | ₹157.89 Cr | ₹165.67 Cr | ₹186.05 Cr | ₹67.25 Cr | ₹119.36 Cr | ₹55.05 Cr |
| Total Tax Expense | ₹72.57 Cr | ₹55.51 Cr | ₹40.27 Cr | ₹42.88 Cr | ₹46.5 Cr | ₹17.05 Cr | ₹32.44 Cr | ₹14.6 Cr |
| Net Profit | ₹233.7 Cr | ₹258.85 Cr | ₹117.62 Cr | ₹122.79 Cr | ₹139.56 Cr | ₹50.2 Cr | ₹86.92 Cr | ₹40.45 Cr |
| Other Comprehensive Income | ₹1.32 Cr | -₹22.5 Lakh | -₹22.5 Lakh | -₹22.4 Lakh | -₹80.1 Lakh | -₹11.3 Lakh | -₹7.5 Lakh | -₹22.4 Lakh |
| Total Comprehensive Income | ₹235.02 Cr | ₹258.63 Cr | ₹117.4 Cr | ₹122.57 Cr | ₹138.76 Cr | ₹50.09 Cr | ₹86.85 Cr | ₹40.22 Cr |
| EBITDA (computed) | ₹398.59 Cr | ₹438.8 Cr | ₹247.34 Cr | ₹249.52 Cr | ₹267.03 Cr | ₹143.83 Cr | ₹207.09 Cr | ₹147.69 Cr |
| Basic EPS | ₹12.33 | ₹13.65 | ₹6.21 | ₹6.48 | ₹7.37 | ₹2.65 | ₹4.62 | ₹2.23 |
| Diluted EPS | ₹12.33 | ₹13.65 | ₹6.21 | ₹6.48 | ₹7.37 | ₹2.65 | ₹4.62 | ₹2.23 |
Shareholding Pattern of Emcure Pharmaceuticals Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 77.87%, foreign institutional investors hold 3.35%, domestic institutional investors hold 6.10%, retail and other public shareholders hold 12.68% of Emcure Pharmaceuticals Limited. The company had 122,189 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 77.87% | 77.87% | 77.88% | 77.91% | 77.92% | 77.94% |
| Public | 22.13% | 22.13% | 22.12% | 22.09% | 22.08% | 22.06% |
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Promoters | 77.87% | 77.92% |
| Public | 22.13% | 22.08% |
| Promoter change (YoY, %pts) | -0.05 | - |
Board & Governance of Emcure Pharmaceuticals Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Emcure Pharmaceuticals Limited has 10 directors - 4 independent and 5 executive. The board is chaired by Berjis Minoo Desai.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Berjis Minoo Desai | Non-Executive - Non Independent Director · Chairperson | 1997-04-03 | 6 |
| Satish Ramanlal Mehta | Executive Director · CEO-MD | 1981-04-16 | 1 |
| Sunil Rajanikant Mehta | Executive Director | 2013-06-05 | 1 |
| Namita Vikas Thapar | Executive Director | 2014-07-28 | 2 |
| Samit Satish Mehta | Executive Director | 2022-07-28 | 1 |
| Mukund Keshao Gurjar | Executive Director | 2001-07-23 | 1 |
| Palamadai Sundararajan Jayakumar | Non-Executive - Independent Director | 2020-07-22 | 7 |
| Vijay Keshav Gokhale | Non-Executive - Independent Director | 2021-04-16 | 2 |
| Vidya Rajiv Yeravdekar | Non-Executive - Independent Director | 2021-04-16 | 2 |
| Shailesh Kripalu Ayyangar | Non-Executive - Independent Director | 2023-06-02 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Palamadai Sundararajan Jayakumar (Chairperson), Berjis Minno Desai, Vijay Keshav Gokhale |
| Nomination and remuneration committee | Vijay Keshav Gokhale (Chairperson), Palamadai Sundararajan Jayakumar, Berjis Minoo Desai |
| Stakeholders Relationship Committee | Berjis Minno Desai (Chairperson), Satish Ramanlal Mehta, Vijay Keshav Gokhale |
| Risk Management Committee | Shailesh Kripalu Ayyangar (Chairperson), Palamadai Sundararajan Jayakumar, Vijay Keshav Gokhale, Sunil Rajanikant Mehta |
| Corporate Social Responsibility Committee | Sunil Rajanikant Mehta (Chairperson), Samit Satish Mehta, Vijay Keshav Gokhale |
Group Structure of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Emcure Pharmaceuticals Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Gennova Biopharmaceuticals Limited | U24231PN2001PLC016253 | - |
| Zuventus Healthcare Limited | U85320PN2002PLC018324 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Emcure Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Dec 2025 | Citi Bank N.A. | ₹150 Cr | Open |
| 19 Sep 2025 | Others | ₹100 Cr | Open |
| 12 Jun 2025 | Others | ₹250 Cr | Open |
| 15 May 2024 | Others | ₹100 Cr | Open |
| 04 May 2023 | Others | ₹175 Cr | Open |
Total charge records: 132 View all charges
Employees and EPFO Compliance at Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited has a workforce of 6,877 employees as of Mar 03, 2025.
Employee Count & EPFO Data of Emcure Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Emcure Pharmaceuticals Limited
GSTIN & GST Filing Data of Emcure Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Emcure Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Emcure Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Emcure Pharmaceuticals Limited
MSME Payment Delays by Emcure Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Emcure Pharmaceuticals Limited
Subsidiaries & Group Companies of Emcure Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Emcure Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Emcure Pharmaceuticals Limited
MCA Filings & Documents of Emcure Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Emcure Pharmaceuticals Limited
Recent News on Emcure Pharmaceuticals Limited
Frequently Asked Questions about Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is an active public limited company in the pharma sector based in Pune City, Maharashtra, India. It was incorporated on 16 April 1981 (45+ years old) and is registered under CIN L24231PN1981PLC024251. The company has 6,877 employees.
Emcure Pharmaceuticals Limited reported revenue of ₹7,963.26 Cr for FY 2025 (up 19.00% YoY).
The current directors of Emcure Pharmaceuticals Limited are:
- Shailesh Kripalu Ayyangar
- Satish Ramanlal Mehta
- Vijay Keshav Gokhale
- Berjis Minoo Desai
- Chetan Rajendra Sharma
- Tajuddin Sabir Shaikh
- Samit Satish Mehta
- Sunil Rajanikant Mehta
- Mukund Keshao Gurjar
- Vidya Rajiv Yeravdekar
- Palamadai Sundararajan Jayakumar
- Namita Vikas Thapar
- Chetan Sharma
The primary industry of Emcure Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Emcure Pharmaceuticals Limited is a listed company.
Emcure Pharmaceuticals Limited can be reached at the registered office: Plot No. P – 1 & P – 2 It – Bt Park, Phase – Ii M.I.D.C, Pune City, Maharashtra, India – 411057, or through the website emcure.co.in.